These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37116624)

  • 41. The role of activin: the other side of chronic kidney disease-mineral bone disorder?
    Cianciolo G; La Manna G; Capelli I; Gasperoni L; Galassi A; Ciceri P; Cozzolino M
    Nephrol Dial Transplant; 2021 May; 36(6):966-974. PubMed ID: 32940690
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current concepts and management strategies in chronic kidney disease-mineral and bone disorder.
    Chauhan V; Kelepouris E; Chauhan N; Vaid M
    South Med J; 2012 Sep; 105(9):479-85. PubMed ID: 22948328
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?
    Figurek A; Spasovski G
    Int Urol Nephrol; 2018 Oct; 50(10):1863-1870. PubMed ID: 30030677
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The current status of chronic kidney disease-mineral and bone disorder management in China.
    Zhan Y; He X; Hong D; Wang L; Li G
    Sci Rep; 2022 Oct; 12(1):16694. PubMed ID: 36202866
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inositol 1,4,5-trisphosphate receptor type 2 is associated with the bone-vessel axis in chronic kidney disease-mineral bone disorder.
    Xiao Q; Tang Y; Luo H; Chen S; Tang Q; Chen R; Xiong L; Xiao J; Hong D; Wang L; Li G; Li Y
    Ren Fail; 2023 Dec; 45(1):2162419. PubMed ID: 36645057
    [No Abstract]   [Full Text] [Related]  

  • 47. High prevalence of biochemical disturbances of chronic kidney disease - mineral and bone disorders (CKD-MBD) in a nation-wide peritoneal dialysis cohort: are guideline goals too hard to achieve?
    Weissheimer R; Bucharles SGE; Truyts CAM; Jorgetti V; Figueiredo AE; Barrett P; Olandoski M; Pecoits-Filho R; Moraes TP
    J Bras Nefrol; 2021; 43(2):173-181. PubMed ID: 33538758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Calcium, phosphate and parathyroid metabolism in kidney transplanted patients.
    Ambrus C; Molnar MZ; Czira ME; Rosivall L; Kiss I; Remport A; Szathmari M; Mucsi I
    Int Urol Nephrol; 2009 Dec; 41(4):1029-38. PubMed ID: 19701690
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
    Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FGF23 Actions in CKD-MBD and other Organs During CKD.
    Sun T; Yu X
    Curr Med Chem; 2023; 30(7):841-856. PubMed ID: 35761503
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oh, My Gut! New insights on the role of the gastrointestinal tract and the gut microbiome in chronic kidney disease-mineral and bone disorder.
    Mirmohammadali SN; Gallant KMH; Biruete A
    Curr Opin Nephrol Hypertens; 2024 Mar; 33(2):226-230. PubMed ID: 38088374
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation between soluble klotho and chronic kidney disease-mineral and bone disorder in chronic kidney disease: a meta-analysis.
    Fan Z; Wei X; Zhu X; Yang K; Tian L; Du Y; Yang L
    Sci Rep; 2024 Feb; 14(1):4477. PubMed ID: 38396063
    [TBL] [Abstract][Full Text] [Related]  

  • 53. International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps.
    Liabeuf S; McCullough K; Young EW; Pisoni R; Zee J; Reichel H; Pecoits-Filho R; Port FK; Stengel B; Csomor PA; Metzger M; Robinson B; Massy ZA
    Bone; 2019 Dec; 129():115058. PubMed ID: 31493530
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The WNT/β-catenin system in chronic kidney disease-mineral bone disorder syndrome.
    Zhang L; Adu IK; Zhang H; Wang J
    Int Urol Nephrol; 2023 Oct; 55(10):2527-2538. PubMed ID: 36964322
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults.
    Bellorin-Font E; Ambrosoni P; Carlini RG; Carvalho AB; Correa-Rotter R; Cueto-Manzano A; Jara A; Jorgetti V; Negri AL; Olaizola I; Salusky I; Slatopolsky E; Weisinger JR; ;
    Nefrologia; 2013; 33 Suppl 1():1-28. PubMed ID: 23629678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
    J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Chronic kidney disease - Mineral bone disorders: Physiopathology and guidelines].
    Lavainne F; Guillot P; Figueres L
    Rev Med Interne; 2022 Apr; 43(4):225-232. PubMed ID: 35227526
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease.
    Zhou C; Wang F; Wang JW; Zhang LX; Zhao MH
    Chin Med J (Engl); 2016 Oct; 129(19):2275-80. PubMed ID: 27647184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Advanced Glycation End-Products (AGE) Lowering Drug ALT-711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD-MBD.
    Chen NX; Srinivasan S; O'Neill K; Nickolas TL; Wallace JM; Allen MR; Metzger CE; Creecy A; Avin KG; Moe SM
    J Bone Miner Res; 2020 Mar; 35(3):608-617. PubMed ID: 31743501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.